Spectrum Pharmaceuticals

FDA OK’s Spectrum Cancer Drug for Wider Use

Spectrum Pharmaceuticals

An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.

Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.

General: